Dermatologica Sinica

: 2023  |  Volume : 41  |  Issue : 1  |  Page : 1--2

Biomarker for rosacea?

Chih-Chiang Chen 
 School of Medicine, College of Medicine, National Yang Ming Chiao Tung University; Department of Dermatology, Taipei Veterans General Hospital, Taipei, Taiwan

Correspondence Address:
Dr. Chih-Chiang Chen
School of Medicine, College of Medicine, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong St., Beitou Dist., Taipei 112

How to cite this article:
Chen CC. Biomarker for rosacea?.Dermatol Sin 2023;41:1-2

How to cite this URL:
Chen CC. Biomarker for rosacea?. Dermatol Sin [serial online] 2023 [cited 2023 May 28 ];41:1-2
Available from:

Full Text

Rosacea is a chronic inflammatory skin disorder characterized by redness, flushing, telangiectasia, and papulopustules on the face. Its diagnosis is typically made by clinical examination, including some major and minor features.[1] However, in some complicated cases, clinical evaluation only might make a misdiagnosis with other skin diseases with mimic clinical appearance, including acne vulgaris, seborrheic dermatitis, lupus, peri-oral dermatitis, etc. To ensure accurate diagnosis, it is imperative to establish the concrete and objective measures as the cornerstone of the diagnostic process. Serum Indoleamine 2,3 Dioxygenase (IDO) is an enzyme that plays a role in the regulation of the immune system, and its level has been found to be elevated in patients with various inflammatory conditions, including rosacea. Odabasi et al.[2] identified that serum IDO levels were significantly higher in patients with rosacea than in healthy controls, particularly in female patients. IDO's high sensitivity and specificity, as observed in the study, may indicate its potential to be a supporting parameter in the diagnosis of rosacea. Further research in this area may provide insight into the pathogenesis of rosacea and lead to new diagnostic and therapeutic approaches for the disease.

The pursuit of a fair complexion has driven the growth of the skin-whitening industry worldwide, which has generated an interest in identifying natural and effective agents to treat hyperpigmentation disorders. Lim et al.[3] explored the potential of coumarin derivatives as anti-melanogenesis agents, focusing on proteins related to the production of excess melanin. Through biocomputational-mediated screening and molecular docking platforms, the authors identified that colladin, farnesiferol C, and novobiocin sodium are promising natural resources for developing anti-melanogenesis agents, which can benefit individuals with hyperpigmentation disorders.

Myositis-specific antibodies (MSAs) can classify dermatomyositis (DM) patients, improving diagnosis and treatment of life-threatening complications. Liu and Yang[4] retrospectively analyzed 33 DM Taiwan patients with MSA testing. Twenty-six patients were MSA-positive, with anti-MDA5 and anti-transcription intermediary factor 1-gamma (TIF-1 γ) being the most commonly detected. Dysphagia was more common in anti-TIF-1 γ (+) patients, while interstitial lung disease was more frequent in anti-MDA5 (+) patients. Four patients had malignancies, with anti-MDA5 (+) patients having a higher mortality rate. This study highlights the importance of MSA evaluation in DM patients for accurate management.

Mortality data in dermatologic diseases are lacking, making it difficult to guide health infrastructure. In this issue of Dermatol Sinica, Saber et al.[5] carried out a retrospective review of 2810 patients with dermatologic diseases who died at a university hospital and found an overall crude mortality of 2.24%. Cutaneous malignancies (53.96%) were the primary causes of death, followed by drug reactions (23.8%). Sepsis (30.74%) was the most common immediate cause of death. The study highlights the need for increased attention to dermatological diseases in mortality data collection and patient management.

Reports of skin reactions following COVID-19 vaccinations are emerging. Lymphocytic thrombophilic arteritis, DM-like skin rash with myopathy, dyshidrotic bullous pemphigoid, and bullous vasculitis after mRNA-1273 and Moderna vaccinations were reported in this issue.[6],[7],[8],[9] Clinicians should be aware of these potential adverse events to guide prompt management.

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1van Zuuren EJ, Arents BW, van der Linden MM, Vermeulen S, Fedorowicz Z, Tan J. Rosacea: New concepts in classification and treatment. Am J Clin Dermatol 2021;22:457-65.
2Odabasi MS, Yazici S, Ozkaya G, Baskan EB, Oral AY. Serum indoleamine 2,3-dioxygenase level and diagnostic value in patients with rosacea. Dermatol Sin 2023;41:25-30.
3Lim JY, Gew LT, Tang YQ. Biocomputational-mediated screening and molecular docking platforms for discovery of coumarinderived antimelanogenesis agents. Dermatol Sin 2023;41:8-17.
4Liu WT, Yang CC. Myositis-specific antibodies in dermatomyositis: A single-center experience of 33 cases in Taiwan. Dermatol Sin 2023;41:31-5.
5Saber M, Faghihi G, Seyedghafouri SA, Hosseini SM. Mortality and cause of death in patients with dermatologic diseases: An 11-year record-based observational study. Dermatol Sin 2023;41:18-24.
6Huang HY, Wu CJ, Lee JY, Liao YC, Hsu CK. Lymphocytic thrombophilic arteritis following mRNA1273 severe acute respiratory syndrome coronavirus 2 vaccination: A case report and review of the literature. Dermatol Sin 2023;41:44-5.
7Chiang J, Lin RY, Lee MS. Two cases with dermatomyositislike skin rash and myopathy following COVID19 vaccination. Dermatol Sin 2023;41:48-9.
8Hsieh TS, Chen JS, Tsai TF. Dyshidrotic bullous pemphigoid developing after Moderna mRNA1273 vaccination. Dermatol Sin 2023;41:52-3.
9Juan CK, Chiu YT, Yen CY. Bullous vasculitis following COVID19 vaccination. Dermatol Sin 2023;41:58-60.